Strategic Alliance DORC operates as a ZEISS company and already integrates with major ophthalmic platforms, suggesting expansion opportunities by co-selling or bundle integrations with ZEISS surgical offerings and other leading equipment providers.

Integrated Platform Recent Eva Nexus VR integration into ZEISS Surgical offerings indicates a momentum for VR and digital-assisted surgery; sales teams should target hospitals and clinics investing in advanced visualization and efficiency tools to complement existing equipment lines.

Proven Stain Adoption TissueBlue FDA-approved ILM stain has broad adoption in the US with high surgeon preference; a compelling upsell path exists for clinics upgrading retina suites or expanding ILM staining capabilities across US and international markets.

Global Expansion With multiple regional distributor partnerships and Health Canada approvals, there is a clear pathway to expand sales via distributor networks in new territories, leveraging existing regulatory milestones to accelerate market entry.

SMB Focus Revenue range and employee count indicate a small-to-mid-sized customer base; targeted outbound and channel strategies should focus on single-site and multi-site ophthalmology practices seeking cost-effective, high-impact equipment and consumables.